Business Context and Reporting Period
Company: MEI Pharma, Inc. (Note: Request metadata listed "Lite Strategy, Inc.", but the filing text identifies the registrant as MEI Pharma, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: September 5, 2017
Event: Entry into a Material Definitive Agreement (License Agreement) with Presage Biosciences, Inc.
Key Financial Metrics and Transaction Terms
This filing reports a strategic licensing agreement rather than periodic financial performance. Key financial terms include:
- Upfront/Near-term Payments: Up to $2.9 million payable to Presage.
- First Indication Milestone: An incremental $2.0 million due upon dosing the first subject in the first registration trial.
- Total Pre-Approval Obligation: $4.9 million total payments up to receipt of marketing approval for the first indication (U.S., E.U., or Japan).
- Additional Milestones: Potential payments of up to $181 million upon achievement of development, regulatory, and commercial milestones.
- Royalties: Mid-single-digit tiered royalties on net sales of successfully developed products.
- Sublicensing Alternative: A tiered percentage of amounts received from sublicensees in lieu of milestone/royalty payments in specific countries.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for MEI Pharma, Inc.
Material Changes and Strategic Shifts
The primary material change is the acquisition of exclusive worldwide rights to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral and selective cyclin-dependent kinase (CDK) inhibitor. This agreement shifts the Company's focus to global commercialization of this specific asset, with the Company assuming sole responsibility for associated costs.
Outlook, Risks, and Contingencies
- Term: The agreement continues country-by-country until the later of patent expiration or regulatory exclusivity expiration.
- Termination Rights (Company): The Company may terminate with 90 days' prior written notice.
- Termination Rights (Presage): Presage may terminate if, after the second anniversary, the Company fails to take certain development actions for 18 months (excluding regulatory delays or manufacturing needs) and has no other material development activities.
- Breach and Bankruptcy: Either party may terminate for material breach (if uncured within 60 days) or bankruptcy/reorganization proceedings (if not dismissed within 60 days).
- Patent Challenge: Presage may terminate if the Company challenges licensed patents.
- Wind-down Obligation: If the Company terminates (excluding Presage breach), it must negotiate to grant Presage an exclusive license to Company-developed IP and transition development/wind down commercialization over 12 months.
Investor Verification Checklist
- Verify the Company's current cash position to ensure it can fund the $2.9 million near-term payment and future development costs.
- Review the clinical status of Voruciclib to assess the timeline for the $2.0 million registration trial milestone.
- Examine the full text of the License Agreement (to be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2017) for redacted confidential terms.
- Confirm the Company's pipeline status to ensure it meets the "material development activities" requirement to avoid termination by Presage after the second anniversary.